Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription


2 Am J Clin Pathol
1 Am J Surg
7 Ann Surg Oncol
5 BMC Cancer
2 Breast Cancer
2 Breast Cancer Res
3 Breast Cancer Res Treat
4 Cancer
1 Cancer Lett
1 Cancer Res
1 Carcinogenesis
3 Clin Breast Cancer
1 Discov Oncol
1 Eur J Surg Oncol
2 Exp Cell Res
4 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Biol Chem
5 J Clin Oncol
2 Lancet Oncol
2 Mod Pathol
1 N Engl J Med
2 NPJ Breast Cancer
1 Oncogene
1 Oncol Rep
2 PLoS One
1 Proc Natl Acad Sci U S A
1 Radiologia (Engl Ed)
1 Radiother Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Pathol

  1. VYAS M, Hissong E, Gonzalez RS, Shia J, et al
    Metastatic Neoplasms Involving the Stomach.
    Am J Clin Pathol. 2022;157:863-873.
    PubMed         Abstract available

  2. YOUSIF M, Huang Y, Sciallis A, Kleer CG, et al
    Quantitative Image Analysis as an Adjunct to Manual Scoring of ER, PgR, and HER2 in Invasive Breast Carcinoma.
    Am J Clin Pathol. 2022;157:899-907.
    PubMed         Abstract available

    Am J Surg

    Time to surgery delays: Barriers to care for black women with breast cancer.
    Am J Surg. 2022 May 21. pii: S0002-9610(22)00308.

    Ann Surg Oncol

  4. HUANG X, Luo Z, Liang W, Xie G, et al
    Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort.
    Ann Surg Oncol. 2022 Jun 3. pii: 10.1245/s10434-022-11911.
    PubMed         Abstract available

  5. HUANG X, Luo Z, Liang W, Xie G, et al
    ASO Visual Abstract: Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort.
    Ann Surg Oncol. 2022 Jun 5. pii: 10.1245/s10434-022-11968.

  6. KUS T, Aktas G
    Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer?
    Ann Surg Oncol. 2022 Jun 4. pii: 10.1245/s10434-022-11979.
    PubMed         Abstract available

  7. EISENBERG ER, Weiss A, Prakash I, Skamene S, et al
    Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort.
    Ann Surg Oncol. 2022 Jun 6. pii: 10.1245/s10434-022-11947.
    PubMed         Abstract available

  8. CROWN A, Muhsen S, Sevilimedu V, Kelvin J, et al
    Fertility Preservation in Young Women with Breast Cancer: Impact on Treatment and Outcomes.
    Ann Surg Oncol. 2022 Jun 7. pii: 10.1245/s10434-022-11910.
    PubMed         Abstract available

  9. KHAN SA, Schuetz S, Hosseini O
    Correction to: Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer: An Educational Review.
    Ann Surg Oncol. 2022 Jun 8. pii: 10.1245/s10434-022-11995.

  10. CHEN JC, Li Y, Fisher JL, Bhattacharyya O, et al
    Modified Radical Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.
    Ann Surg Oncol. 2022 Jun 8. pii: 10.1245/s10434-022-11975.
    PubMed         Abstract available

    BMC Cancer

  11. YELLAPU NK, Ly T, Sardiu ME, Pei D, et al
    Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
    BMC Cancer. 2022;22:627.
    PubMed         Abstract available

  12. OMARINI C, Piacentini F, Sperduti I, Cerma K, et al
    T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.
    BMC Cancer. 2022;22:623.
    PubMed         Abstract available

  13. WANG Y, Song W, Zhou S, Chang S, et al
    The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer.
    BMC Cancer. 2022;22:618.
    PubMed         Abstract available

  14. LI XF, Fu WF, Zhang J, Song CG, et al
    An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
    BMC Cancer. 2022;22:619.
    PubMed         Abstract available

  15. LI X, An C, Zhang W
    Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy.
    BMC Cancer. 2022;22:614.
    PubMed         Abstract available


    A full time job: a year with early-stage breast cancer.
    BMJ. 2022;377:o1421.

    Breast Cancer

  17. ZHANG X, Zhao X, Chang L, Liu F, et al
    LncRNA FOXD3-AS1 promotes breast cancer progression by mediating ARF6.
    Breast Cancer. 2022 Jun 9. pii: 10.1007/s12282-022-01373.
    PubMed         Abstract available

  18. LI Q, Lesseur C, Neugut AI, Santella RM, et al
    The associations of healthy lifestyle index with breast cancer incidence and mortality in a population-based study.
    Breast Cancer. 2022 Jun 3. pii: 10.1007/s12282-022-01374.
    PubMed         Abstract available

    Breast Cancer Res

  19. HARRASSER M, Gohil SH, Lau H, Della Peruta M, et al
    Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Breast Cancer Res. 2022;24:39.
    PubMed         Abstract available

  20. ONG CHC, Lee DY, Lee B, Li H, et al
    Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
    Breast Cancer Res. 2022;24:38.
    PubMed         Abstract available

    Breast Cancer Res Treat

  21. KONISHI T, Fujiogi M, Michihata N, Matsui H, et al
    Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study.
    Breast Cancer Res Treat. 2022 Jun 4. pii: 10.1007/s10549-022-06638.
    PubMed         Abstract available

  22. ELALAOUI SC, Laarabi FZ, Afif L, Lyahyai J, et al
    Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.
    Breast Cancer Res Treat. 2022;194:187-198.
    PubMed         Abstract available

  23. SHERMAN ME, de Bel T, Heckman MG, White LJ, et al
    Serum hormone levels and normal breast histology among premenopausal women.
    Breast Cancer Res Treat. 2022;194:149-158.
    PubMed         Abstract available


  24. CARROLL JE, Olmstead R, Haque R, Irwin MR, et al
    Accelerated mononuclear cell telomere attrition in breast cancer survivors with depression history: A 2-year longitudinal cohort study.
    Cancer. 2022 Jun 7. doi: 10.1002/cncr.34329.
    PubMed         Abstract available

  25. CAO L, Stabellini N, Amin AL, Montero AJ, et al
    Reply to "Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer".
    Cancer. 2022 Jun 7. doi: 10.1002/cncr.34339.

    Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer.
    Cancer. 2022 Jun 7. doi: 10.1002/cncr.34340.

  27. O'ROURKE K
    Breast cancer overdiagnosis through mammograms is lower than previous estimates.
    Cancer. 2022;128:2398-2399.

    Cancer Lett

  28. MEHLICH D, Marusiak AA
    Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Cancer Lett. 2022 Jun 3:215775. doi: 10.1016/j.canlet.2022.215775.
    PubMed         Abstract available

    Cancer Res

  29. ZHANG Z, Golomb L, Meyerson M
    Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
    Cancer Res. 2022;82:2171-2184.
    PubMed         Abstract available


  30. SUMAN P, Mehta V, Craig AWB, Chander H, et al
    Wild-type p53 suppresses formin-binding protein-17 (FBP17) to reduce invasion.
    Carcinogenesis. 2022;43:494-503.
    PubMed         Abstract available

    Clin Breast Cancer

  31. HEYLEN J, Punie K, Smeets A, Neven P, et al
    Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study.
    Clin Breast Cancer. 2022 Apr 30. pii: S1526-8209(22)00076.
    PubMed         Abstract available

  32. SNIDER K, Moore T, Walters C, Brachtenbach T, et al
    An Analysis of the Evidence Informing Clinical Practice Guidelines in the Management and Treatment of Breast Cancer.
    Clin Breast Cancer. 2022 Apr 29. pii: S1526-8209(22)00078.
    PubMed         Abstract available

  33. POTERALA JE, Havighurst T, Braun Wisinski K
    Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies.
    Clin Breast Cancer. 2022 May 5. pii: S1526-8209(22)00080.
    PubMed         Abstract available

    Discov Oncol

  34. RYSPAYEVA D, Halytskiy V, Kobyliak N, Dosenko I, et al
    Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?
    Discov Oncol. 2022;13:43.
    PubMed         Abstract available

    Eur J Surg Oncol

  35. ZWAKMAN M, Francken AB
    Reply to letter to the editor: Long-term quality of life and aesthetic outcomes after breast conserving surgery in patients with breast cancer.
    Eur J Surg Oncol. 2022 May 26. pii: S0748-7983(22)00433.

    Exp Cell Res

  36. XIAO H, Long J, Chen X, Tan MD, et al
    NUPR1 promotes the proliferation and migration of breast cancer cells by activating TFE3 transcription to induce autophagy.
    Exp Cell Res. 2022 Jun 2:113234. doi: 10.1016/j.yexcr.2022.113234.
    PubMed         Abstract available

  37. GAO H, Li H, Wang J, Xu C, et al
    Polyamine synthesis enzyme AMD1 is closely related to the tumorigenesis and prognosis of human breast cancer.
    Exp Cell Res. 2022 Jun 4:113235. doi: 10.1016/j.yexcr.2022.113235.
    PubMed         Abstract available

    Int J Cancer

  38. RATOSA I, Dobnikar N, Bottosso M, Dieci MV, et al
    Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real-world data from a multicentric European cohort.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34135.
    PubMed         Abstract available

  39. WU Z, Byrd DA, Wan Y, Ansong D, et al
    The oral microbiome and breast cancer and non-malignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34145.
    PubMed         Abstract available

  40. HENNINGSEN MB, McWhan K, Dam VS, Mele M, et al
    Amplified Ca(2+) dynamics and accelerated cell proliferation in breast cancer tissue during purinergic stimulation.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34147.
    PubMed         Abstract available

  41. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
    Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  42. LAPEN K, King C, Braunstein LZ, Khan AJ, et al
    A Comparison of Patient- and Clinician-Reported Acute Toxicity During Radiotherapy for Primary Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jun 5. pii: S0360-3016(22)00548.
    PubMed         Abstract available

    J Biol Chem

  43. ZHANG X, Zhang R, Hou C, He R, et al
    FOXF2 oppositely regulates stemness in luminal and basal-like breast cancer cells through the Wnt/beta-catenin pathway.
    J Biol Chem. 2022 May 31:102082. doi: 10.1016/j.jbc.2022.102082.
    PubMed         Abstract available

    J Clin Oncol

  44. MITTENDORF EA, King TA, Tolaney SM
    Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 8:JCO2200173. doi: 10.1200/JCO.22.00173.

  45. CESCON DW, Kalinsky K, DeMichele AM
    Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
    J Clin Oncol. 2022 Jun 4:JCO2201026. doi: 10.1200/JCO.22.01026.

  46. LIPSYC-SHARF M, de Bruin EC, Santos K, McEwen R, et al
    Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2022 Jun 4:JCO2200908. doi: 10.1200/JCO.22.00908.
    PubMed         Abstract available

  47. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.

  48. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed         Abstract available


    Greater Well-being After Breast Conservation Surgery vs Mastectomy.
    JAMA. 2022;327:2066.

    Lancet Oncol

  50. HOWELL SJ, Casbard A, Carucci M, Ingarfield K, et al
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded bi
    Lancet Oncol. 2022 Jun 1. pii: S1470-2045(22)00284.
    PubMed         Abstract available

  51. BRAY F, Parkin DM
    Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.
    Lancet Oncol. 2022;23:719-728.
    PubMed         Abstract available

    Mod Pathol

  52. BACHERT SE, Jen A, Denison C, Kwait D, et al
    Breast lesions associated with mammographic architectural distortion: a study of 588 core needle biopsies.
    Mod Pathol. 2022;35:728-738.
    PubMed         Abstract available

  53. LUCHINI C, Pantanowitz L, Adsay V, Asa SL, et al
    Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring.
    Mod Pathol. 2022;35:712-720.
    PubMed         Abstract available

    N Engl J Med

  54. MODI S, Jacot W, Yamashita T, Sohn J, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
    PubMed         Abstract available

    NPJ Breast Cancer

  55. CORREIA L, Magno R, Xavier JM, de Almeida BP, et al
    Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.
    NPJ Breast Cancer. 2022;8:71.
    PubMed         Abstract available

  56. KUMEGAWA K, Takahashi Y, Saeki S, Yang L, et al
    GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer.
    NPJ Breast Cancer. 2022;8:70.
    PubMed         Abstract available


  57. KUMARASAMY V, Nambiar R, Wang J, Rosenheck H, et al
    RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.
    Oncogene. 2022 Jun 9. pii: 10.1038/s41388-022-02362.
    PubMed         Abstract available

    Oncol Rep

  58. HAM A, Cho MH, Won HS, Jo J, et al
    betacatenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrineresistant breast cancer cells.
    Oncol Rep. 2022;48.
    PubMed         Abstract available

    PLoS One

  59. MEURS CJC, Til JAV, Menke-Pluijmers MBE, Vet S, et al
    Surgeons' preferences for using sentinel lymph node biopsy in patients with ductal carcinoma in situ.
    PLoS One. 2022;17:e0269551.
    PubMed         Abstract available

  60. TANDA N, Tada H, Washio J, Takahashi N, et al
    Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer: A retrospective cohort study.
    PLoS One. 2022;17:e0269335.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  61. WANG G, Kumar A, Ding W, Korangath P, et al
    Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.
    Proc Natl Acad Sci U S A. 2022;119:e2200200119.
    PubMed         Abstract available

    Radiologia (Engl Ed)

  62. GONZALEZ MORENO IM, Trejo-Falcon J, Matsumoto MM, Huertas Moreno M, et al
    Radiology volunteers to support a breast cancer screening program in Peru: Description of the project, preliminary results, and impressions.
    Radiologia (Engl Ed). 2022;64:256-265.
    PubMed         Abstract available

    Radiother Oncol

  63. MIRJOLET C, Diallo I, Bertaut A, Veres C, et al
    Treatment related factors associated with the risk of breast radio-induced-sarcoma.
    Radiother Oncol. 2022;171:14-21.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.